NeoGenomics, Inc.
12701 Commonwealth Drive
Suite 9
Fort Myers
Florida
33913
United States
Tel: 239-768-0600
Fax: 239-768-0711
Website: http://www.neogenomics.org/
Email: info@neogenomics.org
264 articles about NeoGenomics, Inc.
-
NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference
3/1/2024
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced the company will participate in the upcoming TD Cowen 44th Annual Health Care Conference in Boston, Massachusetts.
-
NeoGenomics Reports Fourth Quarter and Full Year 2023 Results
2/20/2024
NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2023 results for the period ended December 31, 2023.
-
NeoGenomics Signs Working with Cancer Pledge in Support of Employees
2/1/2024
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that the Company has signed the Working with Cancer Pledge.
-
NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024
1/30/2024
NeoGenomics, Inc. today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 20, 2024.
-
NeoGenomics and ConcertAI Announce Collaboration to Advance Population-Scale, Definitive Hematological Research & Generative AI Solutions at ASH 2023
1/8/2024
NeoGenomics, Inc., a leading oncology testing services company, and ConcertAI, LLC, a leading oncology real-world evidence data and AI technology company, today announced a broad collaboration to advance large-scale hematological research solution to investigate real-world clinical practice and outcomes in hematological malignancies.
-
NeoGenomics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
1/2/2024
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced the company will participate in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
-
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
12/5/2023
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced new data highlighting its RaDaR® assay for minimal residual disease (MRD) will be presented at the 46th annual San Antonio Breast Cancer Symposium (SABCS).
-
NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference
11/14/2023
NeoGenomics, Inc., a leading oncology testing services company, announced the company will participate in the upcoming Piper Sandler 35th Annual Global Healthcare Conference in New York City.
-
NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios
10/24/2023
NeoGenomics, Inc., a leading oncology testing services company, announced the commercial availability of two new tests, expanding its cancer portfolio of innovative products.
-
NeoGenomics Reports Second Quarter 2023 Results
8/8/2023
NeoGenomics, Inc. today announced its second-quarter results for the period ended June 30, 2023 as compared to June 30, 2022.
-
NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer
7/27/2023
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, announced today that the Molecular Diagnostics Services Program (MolDx) has conveyed coverage for the RaDaR assay, a personalized liquid biopsy for minimal residual disease (MRD) and recurrence detection.
-
NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023
7/18/2023
NeoGenomics, Inc.today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023.
-
NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors
6/29/2023
NeoGenomics, Inc. today announced the appointment of Elizabeth Floegel, Neil Gunn, and Tony Zook to its Board of Directors.
-
NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
6/15/2023
NeoGenomics, Inc. announced that its RaDaR® assay, a personalized liquid biopsy for minimal/molecular residual disease and recurrence detection, has obtained its first pan-cancer commercial coverage by Blue Shield of California.
-
NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer
6/5/2023
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data in support of its RaDaR assay for the detection of molecular residual disease (MRD) and recurrence in patients with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
-
NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
6/1/2023
NeoGenomics, Inc. today announced the company will be participating in the upcoming Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, California.
-
NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO
5/30/2023
NeoGenomics, Inc. today announced new data supporting its cancer tests and treatment guidance tools will be showcased in five poster presentations at the 2023 American Society of Clinical Oncology Annual Meeting taking place June 2-6 in Chicago, Illinois.
-
NeoGenomics Reports First Quarter 2023 Results
5/8/2023
NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced its first-quarter results for the period ended March 31, 2023.
-
NeoGenomics to Participate at the BofA Securities 2023 Healthcare Conference
5/3/2023
NeoGenomics, Inc.today announced the company will be participating in the upcoming BofA Securities 2023 Healthcare Conference in Las Vegas, Nevada.
-
NeoGenomics to Announce First Quarter 2023 Financial Results
4/17/2023
NeoGenomics, Inc. announced today that it will release its first quarter 2023 financial results on Monday, May 8, 2023.